A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
about
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaStem cell transplantation for neuroblastomaImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteCytotoxicity of activated natural killer cells against pediatric solid tumors.Antibody Therapies in Cancer.Immune-based therapeutics for pediatric cancer.Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 studyImmunotherapy of childhood cancer: from biologic understanding to clinical application.New aspects of neuroblastoma treatment: ASPHO 2011 symposium reviewImmunotherapy for pediatric cancer.Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Anti-GD2 Strategy in the Treatment of NeuroblastomaEngineering anti-GD2 monoclonal antibodies for cancer immunotherapy.Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies.Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.GD2-targeted immunotherapy and radioimmunotherapyDifferential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.Antibody-based immunotherapy in high-risk neuroblastoma.28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures.Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.Rare presentations of primary melanoma and special populations: a systematic review.Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISAComparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastomaIncreasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Promising therapeutic targets in neuroblastomaIntratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.Advances in paediatric cancer treatmentRESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.Immunology and immunotherapy of neuroblastomaIntratumoral immunocytokine treatment results in enhanced antitumor effects.(19)F-MRI for monitoring human NK cells in vivoIntratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial EfficiencyRole of IL-2 in cancer immunotherapy
P2860
Q24602657-C9DAA979-2FAD-4603-9381-512AD6C0AE1AQ24629221-2B72C637-3003-455E-9D64-06404451DB17Q28066935-D4FCE701-4A70-457F-B588-FFEA2D6FC37EQ30503995-8498D041-8285-485B-B73F-2BE3FF4CAD87Q31104000-7D3E49ED-C42D-4E21-8609-AC4DFC5AA249Q33604121-EC19CDD5-E58E-4AF8-A687-5F6356FB9707Q33605532-9DC46498-B0DB-4D8D-B0A2-998F9EE95B09Q33691441-AD9610EA-50E0-45B3-AE8E-1F1669CA2508Q33752982-56B09C52-5484-46E2-ACD5-6544CB8B54F8Q33922797-0216234D-B616-496E-BD3F-DB24F3547B8BQ33924586-9CFBF493-DD02-49D3-AD98-EA3028FD96ECQ33964937-0074542B-2F95-4EA8-890A-5B14F8F0BB55Q34129154-1F760B9C-E650-4BD4-8EFA-84759C2B3B7AQ34186886-681D763A-6D0E-4A13-A0D6-36C704D79B38Q34243887-CF38153B-82AB-4354-A776-FFB8D347B0C5Q34389202-401C3343-254D-47CF-8C39-B0B7E819A215Q34424834-5CCD340B-915B-42B4-B957-000504858FF3Q34484061-F5601EB9-6E5E-48A2-B940-3CBA30C4DE09Q34488726-1614754E-0208-4A5C-8F0F-A567287033F7Q34625339-D293D0F2-181A-479B-8A61-DEE5BE449356Q34683623-2FF242EA-A4F5-42DD-9B7C-7FAE6DDA08A3Q34725758-22066DA1-75A8-4B46-ADFC-47649ECC6911Q34785880-ABB53FE5-E1AB-48F3-A2BB-42C4276CF7C6Q35077759-E288F5BA-E39D-42AD-8319-338553CC359EQ35147046-BB85C218-CA7A-4D86-B2B3-022B0F74EF5CQ35381031-A36D3C78-BD40-4E45-A7DC-FC2BCCDBFD34Q35587509-F63B2285-1907-47ED-9214-03BC0758C63CQ35604043-80F3F697-A924-4D58-BEC0-B2AF68F1E3EFQ35963440-1CEF7A73-5A8F-4787-9C8B-2C64D15F7F70Q36055313-4FAD18FD-EAB9-4CC1-B577-C46E3C577B89Q36179663-17414A3A-9647-4790-B4C7-9F2ACA04B0C5Q36412879-A2308EC3-A959-43E5-9352-8CAB580D2C7AQ36508630-166368D9-3F4A-49CE-A858-C248E2E54ADAQ36776358-EB3CC65B-5CB6-4BB8-9DFF-3B45DAF8E7CFQ36856798-19EAF7F4-9753-4EC3-B6C6-3AF508DA3E23Q36953492-5B58D3BE-C708-47B0-8260-6DD7D44BA221Q37012655-6B1CFC0B-348A-44AA-801A-4377AF371CD9Q37038652-AB15B2BE-1ADD-4F58-8BAC-416709196749Q37048013-A315F5CB-5D76-41F5-A346-3D04871DAFC6Q37079072-E3B4551B-869D-4211-8E64-35ED0BAF3DD2
P2860
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase I clinical trial of th ...... the Children's Oncology Group
@ast
A phase I clinical trial of th ...... the Children's Oncology Group
@en
type
label
A phase I clinical trial of th ...... the Children's Oncology Group
@ast
A phase I clinical trial of th ...... the Children's Oncology Group
@en
prefLabel
A phase I clinical trial of th ...... the Children's Oncology Group
@ast
A phase I clinical trial of th ...... the Children's Oncology Group
@en
P2093
P2860
P1476
A phase I clinical trial of th ...... the Children's Oncology Group
@en
P2093
Adam G Sternberg
Children's Oncology Group
Clare Twist
Jacquelyn A Hank
Jens Eickhoff
Kaci L Osenga
Katherine K Matthay
Mark Krailo
Mark R Albertini
P2860
P304
P356
10.1158/1078-0432.CCR-05-2000
P407
P50
P577
2006-03-01T00:00:00Z